Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT01095146
Other study ID # K-PAE-10-284
Secondary ID
Status Enrolling by invitation
Phase N/A
First received March 29, 2010
Last updated March 29, 2010
Start date March 2010
Est. completion date January 2012

Study information

Verified date March 2010
Source Amrita Institute of Medical Sciences & Research Center
Contact n/a
Is FDA regulated No
Health authority India: Indian Council of Medical Research
Study type Observational

Clinical Trial Summary

Macrophage activation syndrome(MAS) is a complication of bone marrow suppression, coagulopathy and CNS dysfunction which occurs in rheumatic diseases. Normally the (Hemophagocytic Lympho-Histiocytosis) HLH-2004 criteria is used to diagnose patients with MAS. However this criteria is probably not sensitive and would probably be fulfilled quite late into the disease. Thus there would be an unacceptable delay. Ravelli et al came up with a different set of criteria based on data of patients reported in literature.

Systemic onset juvenile idiopathic arthritis (SoJIA) is the most common cause of MAS. MAS in other rheumatic illnesses occurs in the setting on unbridled inflammation. In both SoJIA and uncontrolled rheumatic disease the patient is liable to have high WBC counts and high platelet counts. Bone marrow suppression which is one of the pathognomic features of MAS would be picked up very late if absolute cut off values were utilized. Kelly et al used the same arguments in their review to suggest that in MAS/Reactive hemophagocytic lymphohistiocytosis(ReHLH), the trend of change in laboratory parameters would be more useful than absolute cut offs. Hence the investigators propose new candidate criteria which are based on trends of laboratory parameters and seek to determine their utility in comparison to absolute cut offs of HLH or Ravelli criteria. The investigators also wanted to determine that among the Ravelli criteria and HLH-2004 criteria, which were fulfilled earlier in patients diagnosed as having MAS.

Study hypothesis:-Criteria which measure serial trend of laboratory parameters would be fulfilled earlier than absolute cut offs when diagnosing MAS in patients with rheumatic illness.


Description:

Read more »
Read more »

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
India Amrita Institute of Medical Sciences Cochin Kerala

Sponsors (1)

Lead Sponsor Collaborator
Amrita Institute of Medical Sciences & Research Center

Country where clinical trial is conducted

India, 

References & Publications (3)

Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. — View Citation

Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol. 2007 Sep;19(5):477-81. Review. — View Citation

Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, Viola S, Martini A. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005 May;146(5):598-604. Review. — View Citation

See also
  Status Clinical Trial Phase
Recruiting NCT06405152 - Assessment of Macrophage Activation syndromE in STill's Disease
Not yet recruiting NCT03721809 - Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis N/A
Active, not recruiting NCT02780583 - Treatment of Macrophage Activation Syndrome (MAS) With Anakinra Phase 1
Active, not recruiting NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT06339177 - Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Recruiting NCT02569463 - Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome(MAS) Phase 1/Phase 2
Not yet recruiting NCT05137496 - Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome Phase 3
Active, not recruiting NCT03827343 - Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Recruiting NCT05611710 - Anakinra in Dengue With Hyperinflammation ( AnaDen ) Phase 2
Completed NCT03311854 - A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) Phase 2
Recruiting NCT05001737 - Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Phase 3
Completed NCT03332225 - A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis Phase 2
Completed NCT04339712 - Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction Phase 2